NEW YORK – Vivace Therapeutics on Wednesday said it has raised $30 million in a Series C financing round, which it plans to put toward advancing an investigational cancer agent targeting the Hippo-YAP pathway.
The financing round was led by Boxer Capital, with participation from RA Capital Management and Canaan partners. Norman Zhou of Boxer Capital will join Vivace's board of directors.